PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Artificial pancreas technology set to change lives

Emerging technology could help patients who are unable to manage their type 1 diabetes.

Individuals who are typically unable to manage their type 1 diabetes will be offered new technology to help them control their condition. Furthermore, the assistance is delivered with little human input.

An independent National Institute for Health and Care Excellence (NICE) committee has recommended the use of hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes, with the technology described as a step towards an artificial pancreas.

The technology transmits data to a body-worn insulin pump which uses the data to run a mathematical calculation in order to work out how much insulin needs to be delivered into the body to keep blood glucose levels within a healthy range.

It effectively allows patients with type 1 diabetes to go about their day-to-day lives without having to continuously monitor blood glucose levels.

When type 1 diabetes is not well controlled, patients are often at risk of long-term complications such as blindness, amputations, or kidney problems.

NICE has recommended that patients who are unable to control their condition in spite of using an insulin pump – or real-time or intermittently scanned continuous glucose monitoring – are offered the technology if their long-term average blood glucose levels suggest they are at risk of long-term complications.

Those patients who are pregnant or planning a pregnancy are also eligible because blood glucose levels are harder to manage during this time.

Mark Chapman, interim director of medical technology at NICE, explained: “Some people living with type 1 diabetes struggle to manage their condition, even though they are doing everything asked of them by their diabetes team. This technology is the best intervention to help them control their diabetes, barring a cure.”

“Our committee has reviewed the real-world data generated by the NHS and evidence generated by randomised controlled trials which show there are clear benefits of recommending the technology’s use. We look forward to working with NHS England and industry to ensure a cost-effective price can be reached which is fair to taxpayers,” he added.

Around 105,000 patients in England are set to be offered the technology. Meanwhile, it is estimated that approximately 278,000 people in England and Wales are living with type 1 diabetes.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026